First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

Disease indications for drugs have conventionally been defined by pathologic processes, signs or symptoms, or histologic findings in affected organs. Oncology has defined subtypes of organ-specific cancers on the basis of tumor markers; in many instances, markers are used to select patients who may…

http://ift.tt/2wQPuQS